Medical rehabilitation is a research and clinical concern across the age span. Premature infants require rehabilitation of multiple types (physical, respiratory, occupational), children with cerebral palsy and spina bifida have extensive rehabilitation needs. Adults with spinal cord, brain, and limb trauma all require extensive rehabilitation support. Research to improve functional outcomes, and understand the pathophysiology of specific disabilities is important, both for patient quality of life, as well as burden on the health care system. The goal of our NCMRR-DC Core is to provide technical services and training across both molecular and functional outcome measures in rehabilitation research. During the previous award period, our NCMRR Core provided services and training to 108 principal investigators in 32 institutions, with processing and analysis of >4,500 samples. Didactic and outreach efforts included >3,500 hrs of on-site training of external investigators, 95 invited lectures, 29 presentations at national and international conferences, and organization of workshops to write and disseminate standard operating procedures for functional outcome measures. In this competitive renewal application, the PIs have extended their molecular outcomes services and training to include murine and human functional outcomes. These include clinical evaluator services and training, a murine functional testing facility, and facilitation of ancillary studies in pre-existing human cohorts emphasizing functional outcomes. These new resources have been established over the last 4 years, have been heavily utilized by the international rehabilitation research community, and are now proposed as a part of the NCMRR-DC Core.
Research to improve functional outcomes, and understand the pathophysiology of specific disabilities is important, both for patient quality of life, as well as burden on the health care system. The goal of the NCMRR-DC Core is to provide technical services and training across both molecular and functional outcome measures in rehabilitation research.
|Darnall, Robert A; Chen, Xi; Nemani, Krishnamurthy V et al. (2017) Early postnatal exposure to intermittent hypoxia in rodents is proinflammatory, impairs white matter integrity, and alters brain metabolism. Pediatr Res 82:164-172|
|Chen, Yi-Wen; Gregory, Chris; Ye, Fan et al. (2017) Molecular signatures of differential responses to exercise trainings during rehabilitation. Biomed Genet Genom 2:|
|Jain, H V; Boehler, J F; Verthelyi, D et al. (2017) An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes. RSC Adv 7:42519-42528|
|Defour, Aurelia; Medikayala, Sushma; Van der Meulen, Jack H et al. (2017) Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle. Hum Mol Genet 26:1979-1991|
|Vila, Maria C; Rayavarapu, Sree; Hogarth, Marshall W et al. (2017) Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy. Cell Death Differ 24:330-342|
|Al-Shargabi, T; Govindan, R B; Dave, R et al. (2017) Inflammatory cytokine response and reduced heart rate variability in newborns with hypoxic-ischemic encephalopathy. J Perinatol 37:668-672|
|Paget, Sonia; Dubuissez, Marion; Dehennaut, Vanessa et al. (2017) HIC1 (hypermethylated in cancer 1) SUMOylation is dispensable for DNA repair but is essential for the apoptotic DNA damage response (DDR) to irreparable DNA double-strand breaks (DSBs). Oncotarget 8:2916-2935|
|Munters, Li Alemo; Loell, Ingela; Ossipova, Elena et al. (2016) Endurance Exercise Improves Molecular Pathways of Aerobic Metabolism in Patients With Myositis. Arthritis Rheumatol 68:1738-50|
|Hibino, Narutoshi; Best, Cameron A; Engle, Alyson et al. (2016) Novel Association of miR-451 with the Incidence of TEVG Stenosis in a Murine Model. Tissue Eng Part A 22:75-82|
|Loell, Ingela; Raouf, Joan; Chen, Yi-Wen et al. (2016) Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents. Arthritis Res Ther 18:136|
Showing the most recent 10 out of 127 publications